T1	Participants 177 242	Cutaneous Lymphoma Task Force phase III randomized clinical trial
T2	Participants 335 369	early stages of mycosis fungoides.
T3	Participants 569 625	patients treated with PUVA alone or PUVA and bexarotene.
T4	Participants 765 821	in patients with stage IB and IIA mycosis fungoides (MF)
T5	Participants 997 1030	after 93 of 145 required patients
T6	Participants 1057 1157	the 93 randomized patients, 87 started treatment, 41 received PUVA and 46 received PUVA + bexarotene
